Neurogene Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Neurogene Inc. (NGNE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $649.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-09.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2017-03-09
- Neurogene Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2016 was $649.00K, a 45.52% increase from fiscal 2015.
- Neurogene Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2015 was $446.00K, a 141.08% increase from fiscal 2014.
- Neurogene Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2014 was $185.00K, a 96.81% increase from fiscal 2013.
- Neurogene Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2013 was $94.00K, a 21.55% decline from fiscal 2012.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month as first filed |
|---|---|---|
| 2016-12-31 | $649.00K 10-K · filed 2017-03-09 | |
| 2015-12-31 | $446.00K 10-K · filed 2017-03-09 | |
| 2014-12-31 | $185.00K 10-K · filed 2017-03-09 | $185.04K 10-K · filed 2015-03-16 |
| 2013-12-31 | $94.00K 10-K · filed 2016-03-14 | $93.66K 10-K · filed 2015-03-16 |
| 2012-12-31 | $119.83K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |